Oncotarget

Research Papers:

Livin/BIRC7 expression as malignancy marker in adrenocortical tumors

Barbara Altieri, Silviu Sbiera, Silvia Della Casa, Isabel Weigand, Vanessa Wild, Sonja Steinhauer, Guido Fadda, Arkadius Kocot, Michaela Bekteshi, Egle M. Mambretti, Andreas Rosenwald, Alfredo Pontecorvi, Martin Fassnacht and Cristina L. Ronchi _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:9323-9338. https://doi.org/10.18632/oncotarget.14067

Metrics: PDF 1519 views  |   HTML 2557 views  |   ?  


Abstract

Barbara Altieri1,2, Silviu Sbiera3, Silvia Della Casa2, Isabel Weigand1, Vanessa Wild3,4, Sonja Steinhauer1, Guido Fadda5, Arkadius Kocot6, Michaela Bekteshi1, Egle M. Mambretti7, Andreas Rosenwald4, Alfredo Pontecorvi2, Martin Fassnacht1,3, Cristina L. Ronchi1

1Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital of Wuerzburg, Germany

2Division of Endocrinology and Metabolic Diseases, Catholic University of the Sacred Heart, Rome, Italy

3Comprehensive Cancer Center Mainfranken, University of Wuerzburg, Germany

4Department of Pathology, University of Wuerzburg, Germany

5Division of Anatomic Pathology and Histology, Catholic University of the Sacred Heart, Rome, Italy

6Department of Urology, University Hospital of Wuerzburg, Germany

7Department of Anesthesiology and Critical Care, University Hospital of Wuerzburg, Germany

Correspondence to:

Cristina L. Ronchi, email: Ronchi_C@ukw.de

Keywords: livin, BIRC7, adrenocortical carcinoma, adrenal tumor, caspase-3

Received: May 27, 2016     Accepted: December 15, 2016     Published: December 21, 2016

ABSTRACT

Livin/BIRC7 is a member of the inhibitors of apoptosis proteins family, which are involved in tumor development through the inhibition of caspases. Aim was to investigate the expression of livin and other members of its pathway in adrenocortical tumors and in the adrenocortical carcinoma (ACC) cell line NCI-H295R.

The mRNA expression of livin, its isoforms α and β, XIAP, CASP3 and DIABLO was evaluated by qRT-PCR in 82 fresh-frozen adrenal tissues (34 ACC, 25 adenomas = ACA, 23 normal adrenal glands = NAG). Livin protein expression was assessed by immunohistochemistry in 270 paraffin-embedded tissues (192 ACC, 58 ACA, 20 NAG). Livin, CASP3 and cleaved caspase-3 were evaluated in NCI-H295R after induction of livin overexpression.

Relative livin mRNA expression was significantly higher in ACC than in ACA and NAG (0.060 ± 0.116 vs 0.004 ± 0.014 and 0.002 ± 0.009, respectively, p < 0.01), being consistently higher in tumors than in adjacent NAG and isoform β more expressed than α. No significant differences in CASP3, XIAP and DIABLO levels were found among these groups. In immunohistochemistry, livin was localized in both cytoplasm and nuclei. The ratio between cytoplasmic and nuclear staining was significantly higher in ACC (1.51 ± 0.66) than in ACA (0.80 ± 0.35) and NAG (0.88 ± 0.27; p < 0.0001). No significant correlations were observed between livin expression and histopathological parameters or clinical outcome. In NCI-H295R cells, the livin overexpression slightly reduced the activation of CASP3, but did not correlate with cell viability.

In conclusion, livin is specifically over-expressed in ACC, suggesting that it might be involved in adrenocortical tumorigenesis and represent a new molecular marker of malignancy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 14067